Journal of Clinical Oncology
Articles in this Issue
Evaluation of atezolizumab, durvalumab, lurbinectedin, and tarlatamab in high-grade extrapulmonary neuroendocrine carcinoma: A multicenter retrospective comparative analysis.
e20115 Background: Small cell lung cancer (SCLC) is the most common high-grade neuroendocrine neoplasm (NEN). SCLC is asso...
Progress of phase II study of MVR-T3011, an IL-12/anti-PD-1 armed oncolytic HSV-1, in high-risk BCG-unresponsive CIS and papillary NMIBC.
4608 Background: MVR-T3011 is a novel Phase II oncolytic immunotherapy candidate based on herpes simplex virus type 1 (HSV...
Real-world efficacy and safety of neoadjuvant pembrolizumab in early-stage triple-negative breast cancer: A systematic review and meta-analysis.
e12638 Background: Neoadjuvant chemotherapy (NACT) has become the standard treatment for early-stage triple-negative breas...
Evaluation of ultrasensitive ddPCR and NGS for circulating tumor HPV DNA in minimal residual disease monitoring and lymph-node metastasis in cervical cancer: A prospective study.
e17511 Background: Circulating tumor HPV DNA (ctHPV) is emerging as a promising biomarker for minimal residual disease (MR...
Single-cell characterization of renal cell carcinoma brain metastasis.
e14013 Background: Brain metastasis (BM) in renal cell carcinoma (RCC) remains a major clinical challenge and is frequentl...
High-throughput phenotypic profiling of patient-derived colon cancer organoids to reveal a chemoresistant, AKT-driven tumor subpopulation and treatment strategy.
e15073 Background: Colorectal cancer (CRC) remains a significant clinical challenge due to its intrinsic heterogeneity, th...
Monoclonal gammopathy–associated autoinflammation: A systematic review and meta-analysis of Schnitzler syndrome.
e19579 Background: Schnitzler syndrome is a rare, underdiagnosed disorder that usually presents with late-onset systemic i...
Preliminary results from an ongoing phase 1 study of LB2102, a dnTGFBR2-armored DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory SCLC or LCNEC.
8012 Background: Delta-like ligand 3 (DLL3) is a promising target for small cell lung cancer (SCLC) and other neuroendocri...
Phase 1 study of the tetravalent death receptor 5 agonist ozekibart (INBRX-109) combined with chemotherapy in locally advanced or metastatic, unresectable colorectal adenocarcinoma (CRC).
3533 Background: Patients with metastatic CRC are typically treated with fluorouracil-based chemotherapy in combination wi...
Breath analysis of volatile organic compounds with mid-infrared laser spectroscopy in a cohort of lung cancer patients and control subjects.
8029 Background: Exhaled volatile organic compounds (VOCs) represent potential non-invasive biomarkers for lung cancer det...
A meta-analysis of perioperative immunotherapy modalities in patients with dMMR/MSI-H gastric and gastroesophageal junction adenocarcinoma.
e16127 Background: Immunotherapy for deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) gastric/gastro...
Evaluation of AI-guided questioning versus standard information delivery in a simulated newly diagnosed breast cancer population.
1623 Background: Patients newly diagnosed with breast cancer frequently experience information overload and anxiety, which...
Donor-dependent amplification capacity and phenotype of ex vivo–expanded iNKT cells.
e14526 Background: Invariant natural killer T (iNKT) cells combine rapid innate-like effector function with T-cell specifi...
Bulumtatug fuvedotin (BFv; 9MW2821) plus toripalimab in perioperative patients with muscle-invasive bladder cancer (MIBC): Results of cohort A from a phase 2 study.
4609 Background: Radical cystectomy with pelvic lymph node dissection (RC+PLND) has always been the standard treatment for...
Phase I, multicenter, first-in-human (FIH) global study of SIM0505, an anti-CDH6 (CDH6) antibody-drug conjugate (ADC) in patients with advanced solid tumors.
5580 Background: Cadherin 6 is a transmembrane glycoprotein overexpressed in multiple cancers, including ovarian cancer (O...
Predictive value assessment of the Meet-URO and IMDC scores in metastatic renal cell carcinoma (mRCC) receiving first-line ICI–ICI vs ICI–TKI combinations (Meet-URO 33 study).
e16509 Background: The prognostic value of the IMDC and Meet-URO scores is well-established in clinical trials and real-wo...
HER2-independent antitumor and pharmacodynamic responses to trastuzumab deruxtecan in patients with advanced solid tumors.
3031 Background: Trastuzumab deruxtecan (T-DXd) is a HER2-directed antibody conjugated to topoisomerase 1 inhibitor, derux...
Impact of time-of-day of immune checkpoint inhibitor infusion on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC).
4552 Background: Emerging evidence suggests that circadian rhythms may influence the efficacy of immune checkpoint inhibit...
Prognostic value of baseline 18F-FDG PET/CT in first-line pembrolizumab plus chemotherapy for metastatic triple-negative breast cancer.
e13111 Background: The treatment landscape of metastatic triple-negative breast cancer (mTNBC) is rapidly evolving. Pembro...
Trends in malignant melanoma in the African Union from 1980-2023: Insights from the GBD 2023 study.
e21522 Background: Malignant melanoma is the leading cause of skin cancer deaths worldwide. There is a lower incidence but...
Cancer CARE (Connected Access and Remote Expertise) beyond walls: Pilot, phase 2 clinical trial to evaluate administration of cancer-directed therapy in the patient’s homes versus in clinic in the Florida Panhandle and surrounding areas.
TPS1679 Background: Cancer care in the United States remains highly centralized, imposing substantial time, caregiver, and...
Phase Ib study of momelotinib during and following hematopoietic stem cell transplantation for patients with primary or secondary myelofibrosis.
TPS6607 Background: Despite progress in the treatment of myelofibrosis (MF) with multiple approved JAK inhibitors (JAKi),...
Machine learning (ML)-based prediction of fatal immune checkpoint inhibitor (ICI)–associated myocarditis (MC) with multi-cohort validation.
12019 Background: ICI-associated MC is a rare but highly fatal immune-related adverse event (irAE). Identifying clinical p...
ASCERTAIN: Real-world asciminib (ASC) effectiveness in patients (pts) with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
6526 Background: ATP-competitive tyrosine kinase inhibitors (TKIs) in combination with chemoimmunotherapy have improved ou...
Nutritional and inflammatory factors associated with chemotherapy response and survival in advanced high-grade serous ovarian cancer: A machine learning–based analysis.
e17582 Background: The chemotherapy response score is a well-established prognostic predictor in high-grade serous ovarian...